Avid Bioservices Inc (CDMO)

[biopharm]

Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function.

We found that RTK inhibitors (RTKIs) and VEGF or VEGFR-2 antibodies reversed diabetes when administered at the onset of hyperglycemia.

Finally, examination of human pancreata from patients with T1D revealed that VEGFR-2 was confined to the islet vascularity, which was increased in inflamed islets. Collectively, this work reveals a previously unappreciated role for VEGFR-2 signaling in the pathogenesis of T1D by controlling T-cell accessibility to the pancreatic islets and highlights a novel application of VEGFR-2 antagonists for the therapeutic treatment of T1D.

S. Armando Villalta, Jiena Lang, Samantha Kubeck, Beniwende Kabre, Gregory L. Szot, Boris Calderon, Clive Wasserfall, Mark A. Atkinson, Rolf A. Brekken, Nick Pullen,5 Robert H. Arch, and Jeffrey A. Bluestone.
Diabetes Center and the Department of Medicine, University of California San Francisco, San Francisco, California.
Diabetes

http://bluestonelab.ucsf.edu/node/676